RU2239427C2 - Карбоновые кислоты и их производные и содержащие их фармацевтические композиции - Google Patents

Карбоновые кислоты и их производные и содержащие их фармацевтические композиции Download PDF

Info

Publication number
RU2239427C2
RU2239427C2 RU2000101334/15A RU2000101334A RU2239427C2 RU 2239427 C2 RU2239427 C2 RU 2239427C2 RU 2000101334/15 A RU2000101334/15 A RU 2000101334/15A RU 2000101334 A RU2000101334 A RU 2000101334A RU 2239427 C2 RU2239427 C2 RU 2239427C2
Authority
RU
Russia
Prior art keywords
acid
hnf
hydroxy
group
substituted
Prior art date
Application number
RU2000101334/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2000101334A (ru
Inventor
Якоб БАР-ТАНА (IL)
Якоб БАР-ТАНА
Original Assignee
Йиссум Рисёч Девелопмент Компани Оф Дзе Гебрю Юниверсити Оф Джерусалэм
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йиссум Рисёч Девелопмент Компани Оф Дзе Гебрю Юниверсити Оф Джерусалэм filed Critical Йиссум Рисёч Девелопмент Компани Оф Дзе Гебрю Юниверсити Оф Джерусалэм
Publication of RU2000101334A publication Critical patent/RU2000101334A/ru
Application granted granted Critical
Publication of RU2239427C2 publication Critical patent/RU2239427C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2000101334/15A 1997-06-26 1998-06-23 Карбоновые кислоты и их производные и содержащие их фармацевтические композиции RU2239427C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12116597A IL121165A0 (en) 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof
IL121165 1997-06-26

Publications (2)

Publication Number Publication Date
RU2000101334A RU2000101334A (ru) 2001-11-10
RU2239427C2 true RU2239427C2 (ru) 2004-11-10

Family

ID=11070308

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000101334/15A RU2239427C2 (ru) 1997-06-26 1998-06-23 Карбоновые кислоты и их производные и содержащие их фармацевтические композиции

Country Status (10)

Country Link
US (1) US6303653B1 (enExample)
EP (1) EP1001755B1 (enExample)
JP (1) JP2002507209A (enExample)
CN (2) CN101129349A (enExample)
AT (1) ATE508739T1 (enExample)
AU (1) AU7783998A (enExample)
CA (1) CA2294232A1 (enExample)
IL (2) IL121165A0 (enExample)
RU (1) RU2239427C2 (enExample)
WO (1) WO1999000116A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
WO2002009691A1 (en) * 2000-08-02 2002-02-07 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
AU2001290241A1 (en) * 2000-09-20 2002-04-02 Kyowa Hakko Kogyo Co. Ltd. Tumor cell proliferation inhibitors
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
CN1283610C (zh) 2000-10-11 2006-11-08 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
JP2004532799A (ja) 2000-10-11 2004-10-28 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
WO2003105860A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
JP4931349B2 (ja) 2003-01-23 2012-05-16 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
CA2549995C (en) 2003-12-24 2011-11-15 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2550943A1 (en) * 2003-12-30 2005-07-14 Syndrome X Ltd. Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
WO2007137864A1 (en) * 2006-06-01 2007-12-06 Eucro European Contract Research Gmbh & Co. Kg Use of inhibitors of pp2c for treating or preventing arteriosclerosis
WO2008018877A1 (en) 2006-08-11 2008-02-14 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs, methods of production and uses thereof
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
US8481084B2 (en) 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
DE102007051339A1 (de) * 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
WO2010083311A2 (en) * 2009-01-14 2010-07-22 Vanas Oncology Compositions and methods of use
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
EP2414042A4 (en) * 2009-03-31 2013-01-30 Matthew R Witten RADIATION THERAPY TREATMENT SYSTEM AND METHOD FOR PROVIDING USE OF A MIMETIC OPTIMIZATION ALGORITHM
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
US10479752B2 (en) * 2011-12-08 2019-11-19 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US20180092874A1 (en) * 2016-10-03 2018-04-05 Lincoln Memorial University Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
JP7234151B2 (ja) * 2017-07-07 2023-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 脂肪酸誘導体およびこれらの使用
US12344578B2 (en) 2019-06-21 2025-07-01 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502077A (en) * 1988-08-11 1996-03-26 Norsk Hydro A.S. Fatty acid composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
DE4224670A1 (de) 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
ATE183391T1 (de) * 1993-12-31 1999-09-15 Univ Limburg Verwendung von zusammensetzungen essentieller fettsäuren
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
PL343902A1 (en) * 1997-02-21 2001-09-10 Abbott Lab Methods of and compositions for reducing enteritis and colitis morbidity rate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502077A (en) * 1988-08-11 1996-03-26 Norsk Hydro A.S. Fatty acid composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOCHEM J. 1994, v.298, n. 2, p. 409-414. J. Biol. Chem. 1995, v.270, n. 22, p.1347-1375. *

Also Published As

Publication number Publication date
JP2002507209A (ja) 2002-03-05
WO1999000116A3 (en) 1999-08-12
CA2294232A1 (en) 1999-01-07
WO1999000116A2 (en) 1999-01-07
AU7783998A (en) 1999-01-19
EP1001755B1 (en) 2011-05-11
IL121165A0 (en) 1997-11-20
ATE508739T1 (de) 2011-05-15
IL133540A (en) 2009-09-22
EP1001755A2 (en) 2000-05-24
US6303653B1 (en) 2001-10-16
CN1261274A (zh) 2000-07-26
CN101129349A (zh) 2008-02-27

Similar Documents

Publication Publication Date Title
RU2239427C2 (ru) Карбоновые кислоты и их производные и содержащие их фармацевтические композиции
Iizuka et al. ChREBP-mediated regulation of lipid metabolism: involvement of the gut microbiota, liver, and adipose tissue
Lonardo et al. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?
Lin et al. Different effects of conjugated linoleic acid isomers on lipoprotein lipase activity in 3T3-L1 adipocytes
Sampath et al. Polyunsaturated fatty acid regulation of gene expression
Duplus et al. Is there a single mechanism for fatty acid regulation of gene transcription?
Tobin et al. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-α
Cullingford The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders
Moya-Camarena et al. Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα
Ahmed et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Liu et al. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation
Larsen et al. Nutritional and hormonal regulation of thyroid hormone deiodinases
Auwerx et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR
Jitrapakdee et al. Structure, mechanism and regulation of pyruvate carboxylase
Jeoung et al. Pyruvate dehydrogenase kinase-4 deficiency lowers blood glucose and improves glucose tolerance in diet-induced obese mice
Wanders Peroxisomes in human health and disease: metabolic pathways, metabolite transport, interplay with other organelles and signal transduction
Pramfalk et al. Role of thyroid receptor β in lipid metabolism
Zarei et al. Heme-regulated eIF2α kinase modulates hepatic FGF21 and is activated by PPARβ/δ deficiency
Hein et al. Nuclear receptors and hepatic lipidogenic enzyme response to a dyslipidemic sucrose-rich diet and its reversal by fish oil n-3 polyunsaturated fatty acids
US20040171688A1 (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
Lopes et al. Docosahexaenoic acid (DHA) at the sn-2 position of triacylglycerols increases DHA incorporation in brown, but not in white adipose tissue, of hamsters
Lopez et al. Activation of the rat scavenger receptor class B type I gene by PPARα
Montanaro et al. Role of liver X receptor, insulin and peroxisome proliferator activated receptor α on in vivo desaturase modulation of unsaturated fatty acid biosynthesis
Vaagenes et al. Methylated eicosapentaenoic acid and tetradecylthioacetic acid: effects on fatty acid metabolism
Akpa et al. Inhibition of insulin and T3-induced fatty acid synthase by hexanoate

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110624